Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
COBRA
H3N2
broadly protective vaccine
ferrets
hemagglutination inhibition
influenza
neutralization
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
05
06
2018
accepted:
22
10
2018
pubmed:
16
11
2018
medline:
9
11
2019
entrez:
16
11
2018
Statut:
epublish
Résumé
The vast majority of people already have preexisting immune responses to influenza viruses from one or more subtypes. However, almost all preclinical studies evaluate new influenza vaccine candidates in immunologically naive animals. Recently, our group demonstrated that priming naive ferrets with broadly reactive H1 COBRA HA-based vaccines boosted preexisting antibodies induced by wild-type H1N1 virus infections. These H1 COBRA hemagglutinin (HA) antigens induced antibodies with HAI activity against multiple antigenically different H1N1 viral variants. In this study, ferrets, preimmune to historical H3N2 viruses, were vaccinated with virus-like particle (VLP) vaccines expressing either an HA from a wild-type H3 influenza virus or a COBRA H3 HA antigen (T6, T7, T10, or T11). The elicited antisera had the ability to neutralize virus infection against either a panel of viruses representing vaccine strains selected by the World Health Organization or a set of viral variants that cocirculated during the same time period. Preimmune animals vaccinated with H3 COBRA T10 HA antigen elicited sera with higher hemagglutination inhibition (HAI) antibody titers than antisera elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets. However, while the T11 COBRA vaccine did not elicit HAI activity, the elicited antibodies did neutralize antigenically distinct H3N2 influenza viruses. Overall, H3 COBRA-based HA vaccines were able to neutralize both historical H3 and contemporary, as well as future, H3N2 viruses with higher titers than vaccines with wild-type H3 HA antigens. This is the first report demonstrating the effectiveness of a broadly reactive H3N3 vaccine in a preimmune ferret model.
Identifiants
pubmed: 30429350
pii: JVI.00946-18
doi: 10.1128/JVI.00946-18
pmc: PMC6340030
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Curr Top Microbiol Immunol. 2009;333:397-412
pubmed: 19768416
Clin Vaccine Immunol. 2012 Feb;19(2):128-39
pubmed: 22190399
J Clin Microbiol. 1986 Feb;23(2):240-5
pubmed: 3517049
Clin Infect Dis. 2018 Sep 14;67(7):1129-1131
pubmed: 29672670
J Virol. 2016 Apr 14;90(9):4720-4734
pubmed: 26912624
PLoS Pathog. 2008 May 02;4(5):e1000058
pubmed: 18451985
Vaccine. 2017 Jan 5;35(2):238-247
pubmed: 27914742
Vaccine. 2005 Jan 19;23(9):1144-8
pubmed: 15629357
Protein Eng Des Sel. 2016 Aug;29(8):309-15
pubmed: 27313229
Annu Rev Immunol. 1990;8:737-71
pubmed: 2188678
Curr Opin Immunol. 2014 Jun;28:71-6
pubmed: 24632083
BMC Infect Dis. 2013 Dec 13;13:589
pubmed: 24330575
J Virol Methods. 2012 Jan;179(1):81-9
pubmed: 22044905
J Infect Dis. 2017 Dec 27;217(1):3-11
pubmed: 29294018
Vaccine. 2010 Sep 7;28 Suppl 4:D33-44
pubmed: 20713259
Vaccine. 2016 Jan 20;34(4):495-502
pubmed: 26706277
Influenza Other Respir Viruses. 2017 May;11(3):263-274
pubmed: 28164446
J Virol. 2014 Dec;88(23):13580-92
pubmed: 25210195
Clin Infect Dis. 2013 Jul;57 Suppl 1:S4-S11
pubmed: 23794729
J Virol. 2015 Nov 11;90(2):1116-28
pubmed: 26559834
Curr Opin Immunol. 2018 Aug;53:88-95
pubmed: 29719276
MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):180-185
pubmed: 29447141
Hum Vaccin Immunother. 2015;11(3):572-83
pubmed: 25671661
J Virol. 2017 Nov 30;91(24):
pubmed: 28978710
Hum Vaccin Immunother. 2018;14(8):1840-1847
pubmed: 29641358
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W465-9
pubmed: 18424797
Vaccine. 2006 May 1;24(18):3881-8
pubmed: 16460844
J Infect Dis. 2012 May 15;205(10):1562-70
pubmed: 22448011
Vaccine. 2011 Apr 5;29(16):3043-54
pubmed: 21320540
BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S31
pubmed: 21342562
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409570
Virol J. 2006 Aug 31;3:63
pubmed: 16945126
Int J Mol Sci. 2017 Jul 17;18(7):
pubmed: 28714909
J Virol. 2003 Feb;77(3):2046-55
pubmed: 12525639
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
Sci Rep. 2016 Oct 31;6:36216
pubmed: 27796371
Lancet. 2003 Nov 22;362(9397):1733-45
pubmed: 14643124
J Clin Microbiol. 2008 Jul;46(7):2189-94
pubmed: 18480230
J Virol. 2013 Feb;87(3):1400-10
pubmed: 23115287
J Virol. 2017 Nov 30;91(24):
pubmed: 28978709
Protein Eng Des Sel. 2009 Sep;22(9):543-6
pubmed: 19578121
Euro Surveill. 2017 Oct;22(43):
pubmed: 29090681
Vaccine. 2009 Nov 5;27 Suppl 4:D65-8
pubmed: 19837290